Eledon Pharmaceuticals
ELDN
34 hedge funds and large institutions have $89M invested in Eledon Pharmaceuticals in 2021 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 6 closing their positions.
217% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 6
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
62% more funds holding
Funds holding: 21 → 34 (+13)
58.13% more ownership
Funds ownership: 0% → 58.13% (+58%)
1% more capital invested
Capital invested by funds: $88.4M → $89M (+$589K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$16.8M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
+$5.28M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$5.21M |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
+$3.77M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.41M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$2.58M |
| 2 |
MS
Maven Securities
St Helier,
Jersey
|
-$1.72M |
| 3 |
ACM
Asymmetry Capital Management
San Francisco,
California
|
-$1.23M |
| 4 |
O
OrbiMed
New York
|
-$1.1M |
| 5 |
Morgan Stanley
New York
|
-$495K |
ELDN Hedge Fund Activity: Q1 2021 in Review
34 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Eledon Pharmaceuticals (ELDN) for Q1 2021, worth a combined $89M — up 0.67% from $88.4M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new ELDN positions and 6 closed out — a net gain of 13 holders — while 5 added to existing stakes and 3 trimmed.
The largest buyer was EcoR1 Capital, opening a new position worth an estimated $16.8M. The largest seller was Stonepine Capital Management, exiting entirely with an estimated $2.58M sold.
- 34 institutional investors held Eledon Pharmaceuticals (ELDN) as of Q1 2021, up from 21 in Q4 2020.
- Funds reported $89M of Eledon Pharmaceuticals stock for Q1 2021, up 0.67% quarter-over-quarter.
- 19 funds opened new Eledon Pharmaceuticals positions in Q1 2021 and 6 closed out, a net change of +13 holders.
- The largest Eledon Pharmaceuticals buyer in Q1 2021 was EcoR1 Capital, an estimated $16.8M added.
- The largest Eledon Pharmaceuticals seller in Q1 2021 was Stonepine Capital Management, an estimated $2.58M sold.
Based on aggregated 13F filings for Q1 2021.